Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report Is Abbott's January Pullback a Good Time to Buy? Written by Thomas Hughes. Originally Published: 1/24/2026. 
Quick Look - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 price pullback has made the stock look attractively valued. The decline appears driven more by market angst than by fundamental weakness — a knee-jerk overreaction that has pushed the stock back into the buy zone. 
A growing number of investors are paying attention to developments around private space companies and potential future public listings.
In a recent briefing, one research publisher outlines how some investors are seeking early exposure to the space economy through publicly traded assets — without waiting for a formal IPO. The presentation walks through the structure, risks, and mechanics behind this approach for those who want to understand how it works. Read the full sponsor briefing here The zone in question aligns with market action from 2022 to 2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates The most negative take on Abbott's Q4 results and guidance is that a few metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings accelerated. Revenue growth lagged consensus by several hundred basis points, but margin strength helped offset that shortfall: adjusted earnings per share (EPS) rose 12%, slightly above consensus. Segment results highlighted the resilience of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted — Nutrition declined nearly 9% — but solid growth in Established Pharmaceuticals and Med Tech offset those setbacks. The pharmaceuticals segment grew about 9%, driven by generics and emerging markets, while Med Tech advanced roughly 12.3%, with strength across its sub-segments. Margin developments were positive as well. A favorable product mix, strength in Med Tech, reduced COVID-19 sales and operational improvements left margins ahead of forecasts. Looking ahead, Abbott expects continued improvement, with earnings projected to grow another ~10% in 2026, outpacing revenue growth and supporting its capital return plans. Abbott's capital returns are central to the investment case. The company is a Dividend King, having increased its payout for more than 50 years, and appears positioned to continue doing so. After the pullback the stock yields roughly 2.5%, and Abbott pays out less than half of consensus earnings, leaving room for share buybacks — an important offset to dilution from share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but there were no major rating or price-target changes the morning of the release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth, and that the growth runway remains significant. MarketBeat's consensus share price target suggests as much as 30% upside, potentially setting new all-time highs, while even the low-end targets imply some upside potential. Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, widening margins and strategic acquisitions. The acquisition of Exact Sciences is one example that could broaden Abbott's revenue and profit streams and expand its product pipeline. While the stock's decline has been sharp and could deepen, institutions accumulated shares throughout 2025 and are likely to buy further at discounted prices. Initial technical support appears in the $105 to $110 range, but it is not yet confirmed. The risk is that ABT could dip to the low end of the target buy zone — potentially near $95 or lower — before staging a recovery.
| 
